Category: Blog

The French oncology sector, renowned for its advanced cancer treatment and research facilities, presents a wealth of opportunities for pharmaceutical companies and Contract Research Organizations (CROs) aiming to enter or expand their presence in the French market. This blog post delves into the main cancer centers in France and the current trends, with a focus…

Why Expanded Access is a Game-Changer in Pharma In the dynamic world of pharma and biotech, the spotlight is increasingly on EAP. These programs are not just about bringing medicines to market; they are about bringing hope to patients facing serious or life-threatening diseases. With information more accessible than ever, patients and advocates worldwide are…

Understanding the French Pharmaceutical Landscape As foreign pharmaceutical companies look to expand their reach into the European market, France stands out as a key player. Known for its robust healthcare system and a population keen on high-quality medical care, France offers a promising avenue for growth. However, navigating the regulatory environment can be challenging. A…

The Service Médical Rendu (SMR), or Medical Service Rendered, is a fundamental concept in the French healthcare system, particularly in the context of pharmaceuticals. It is a measure used to evaluate the therapeutic benefit of a medication, which plays a pivotal role in determining its reimbursement by the National Health Insurance (NHI). What is SMR?…

France’s healthcare system is renowned for its efficiency and effectiveness, providing high-quality medical care to its citizens. This success is largely attributed to the various government bodies that oversee different aspects of healthcare. Understanding the roles and connections of these bodies is crucial for anyone looking to engage with the French healthcare sector. Let’s take…

In the heart of France’s innovative healthcare landscape, the Early Access Program (EAP), locally known as “Accès Précoce” (formerly “Autorisation Temporaire d’Utilisation” or ATU), stands as a beacon of hope. This remarkable program bridges the gap between urgent patient needs and medical innovation, offering a lifeline to those facing serious or rare diseases with no…

The pharmaceutical industry is a vast landscape of innovation, regulatory standards, and international processes. As US-based pharmaceutical companies expand their operations and look to tap into the European market, it’s imperative to understand the regulatory environment. One of the most pivotal regulatory pathways for gaining market access in Europe is the Centralised Procedure. Here’s a…

Have a look at our infographic on how the French Pharmaceutical market works, the size and some other valuable information

Are you considering venturing into the realm of off-patent pharmaceutical products? This market segment offers immense opportunities for growth and diversification of your product portfolio. However, navigating the complexities from initial discussions to the final stages of acquisition and transfer can be daunting. That’s where our expertise comes into play. Our Comprehensive Approach At our…

What affects the supply of medicine in the Pharmaceutical Industry? One of the main reasons that prescription drug costs make headlines is because of the actors in the supply chain. This study aims to investigate the reasons for the lack of medicines and their effects on the supply of medicines. We could learn more about…